In The Lancet Diabetes & Endocrinology, John Petrie and colleagues report the main outcome results of the REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL) study,¹ a well designed, double-blind, randomised, placebo-controlled trial in 428 adult patients (40 years and older) with type 1 diabetes and multiple cardiovascular risk factors. The aim of REMOVAL was to investigate the effects of metformin (1000 mg twice daily) on intima-media thickening of the common carotid artery (cIMT)—a surrogate measure of atherosclerosis—as well as on metabolic and other outcomes over 3 years.

中文翻译：

---

二甲双胍在1型糖尿病中的作用

John Petrie及其同事在《柳叶刀糖尿病与内分泌学》杂志中报道了MetfOrmin血管不良病变减少（REMOVAL）研究的主要结局结果，^1这是一项针对428名成年患者进行了精心设计，双盲，随机，安慰剂对照的试验（40岁及以上）与1型糖尿病和多种心血管危险因素。REMOVAL的目的是研究二甲双胍（每天两次1000毫克）对颈总动脉内膜中层增厚（cIMT）（动脉粥样硬化的替代指标）以及在3年内对代谢和其他结局的影响。